Synairgen (LON:SNG) Stock Price Down 16.2% – Here’s What Happened

Shares of Synairgen plc (LON:SNG) fell 16.2% on Monday . The company traded as low as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01). 345,628 shares were traded during trading, a decline of 77% from the average session volume of 1,477,761 shares. The stock had previously closed at GBX 0.84 ($0.01).

Synairgen Stock Down 16.2 %

The stock has a 50 day simple moving average of GBX 1.72 and a 200 day simple moving average of GBX 3.09. The stock has a market cap of £6.86 million, a price-to-earnings ratio of -0.42 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).